Physician profile
Bonnie Gerecke
NPI 1245316827
$8,744.89
in general payments reported to CMS, 2019-2025
37 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $126 · 2021: $157 · 2022: $2,219 · 2023: $2,463 · 2024: $1,565 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,780 · Consulting Fee: $1,663 · Education: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,779.54 |
| Consulting Fee | $1,662.50 |
| Education | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $2,635.55 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $1,924.32 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $834.60 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Amgen INC. | $417.81 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $395.44 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $351.23 | 2019-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $269.10 | 2022-2025 | |
| Nevro Corp. | $233.04 | 2022-2024 | Senza |
| Csl Behring | $175.63 | 2019-2025 | Hizentra |
| Neurocrine Biosciences, INC. | $125.85 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $120.37 | 2024-2025 | Vyepti |
| Tanabe Pharma America, INC. | $111.81 | 2023-2025 | Radicava |
| Horizon Therapeutics Plc | $108.10 | 2023 | Uplizna |
| Genzyme Corporation | $88.24 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $88.23 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $80.58 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Allergan, INC. | $67.55 | 2019-2020 | |
| Ceribell, INC. | $59.45 | 2025 | Pocket Eeg Device |
| Globus Medical, INC. | $56.77 | 2025 | Senza |
| Lilly USA, LLC | $56.49 | 2022 | |
| Grifols USA, LLC | $49.70 | 2024 | Gamunex-C |
| Pfizer INC. | $47.08 | 2023-2024 | |
| Kyowa Kirin, INC. | $44.83 | 2024 | Nourianz |
| Alnylam Pharmaceuticals INC. | $44.10 | 2019 | |
| Janssen Biotech, INC. | $38.41 | 2025 | |
| Medtronic, INC. | $35.29 | 2025 | Aquamantys(Tm) |
| Avanir Pharmaceuticals, INC. | $33.77 | 2019-2022 | |
| Sk Life Science, INC. | $31.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $31.41 | 2023 | Rexulti |
| Amylyx Pharmaceuticals, INC. | $29.04 | 2023 | Relyvrio |
| Catalyst Pharmaceuticals, INC. | $28.21 | 2019 | |
| Tg Therapeutics, INC. | $25.43 | 2023 | |
| Insightec,INC | $25.32 | 2025 | Exablate |
| Biogen, INC. | $24.50 | 2022 | |
| Acadia Pharmaceuticals INC | $20.55 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $20.04 | 2025 | Wainua |
| Acorda Therapeutics, INC | $15.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Gerecke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.